However, there is renewed interest in targeting overactivation of the renin-angiotensin-aldosterone system (RAAS) in CKD due to demonstrable kidney and cardiovascular benefits in large trials of the nonsteroidal MRA finerenone, which was tested on patients with CKD and type 2 diabetes (with albuminuria) who were treated with maximally tolerated doses of a RASi [41, 47, 48], and in HF with mildly reduced or preserved ejection fraction [49]. Here, REN is linked to chronic kidney disease.